 Trevena Inc NASDAQ: TRVN has announced data from 30 patients enrolled in the proof-of-concept study of TRV027 in hospitalized COVID-19 patients. The results showed that TRV027 was well-tolerated and provided initial evidence of its potential to improve biomarker and clinical endpoints associated with COVID-19. 